F-star Announces Strategic Collaboration and Licence Agreement with Takeda to Develop Next-Generation Multi-Specific Antibodies

F-star Therapeutics, an invoX company, has announced a strategic collaboration and license agreement with Takeda to discover and develop next-generation multi-specific antibodies. The collaboration will focus on using F-star's proprietary platforms to research and develop immunotherapies for cancer patients. Under the agreement, F-star and Takeda will work together to research and develop novel ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

Lilly, Takeda Face Class-Action Racketeering Lawsuit Over Diabetes Drug Actos

Pharmaceutical companies Eli Lilly and Takeda are facing a class-action lawsuit over their diabetes drug Actos, which has been certified by a California Federal Judge. The case claims that the drug was marketed without disclosing its risk of bladder cancer, with plaintiffs alleging that both companies misled the FDA about Actos' mechanism to conceal aspects of the drug's safety profile. A Nation..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 9.
  • textsms